Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D.

Clin Cancer Res. 2019 Dec 12. doi: 10.1158/1078-0432.CCR-19-1638. [Epub ahead of print]

PMID:
31831561
2.

Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process.

McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L, Lanceley A.

Int J Gynecol Cancer. 2020 Feb;30(2):221-226. doi: 10.1136/ijgc-2019-000630. Epub 2019 Nov 19.

PMID:
31744886
3.

Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.

Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmaña J, Drew Y, Oza AM, Shapira-Frommer R, Domchek SM, Cameron T, Maloney L, Goble S, Lorusso D, Ledermann JA, McNeish IA.

Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404. doi: 10.1136/ijgc-2019-000623.

PMID:
31685558
4.

Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.

Drew Y, Kristeleit RS, Oaknin A, Ray-Coquard I, Haris NM, Swisher EM.

Oncologist. 2020 Jan;25(1):e109-e119. doi: 10.1634/theoncologist.2019-0229. Epub 2019 Oct 1.

5.

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.

Jones RL, Ratain MJ, O'Dwyer PJ, Siu LL, Jassem J, Medioni J, DeJonge M, Rudin C, Sawyer M, Khayat D, Awada A, de Vos-Geelen JMPGM, Evans TRJ, Obel J, Brockstein B, DeGreve J, Baurain JF, Maki R, D'Adamo D, Dickson M, Undevia S, Geary D, Janisch L, Bedard PL, Abdul Razak AR, Kristeleit R, Vitfell-Rasmussen J, Walters I, Kaye SB, Schwartz G.

Eur J Cancer. 2019 Oct;120:132-139. doi: 10.1016/j.ejca.2019.07.024. Epub 2019 Sep 12.

6.

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.

Evans TRJ, Dean E, Molife LR, Lopez J, Ranson M, El-Khouly F, Zubairi I, Savulsky C, Reyderman L, Jia Y, Sweeting L, Greystoke A, Barriuso J, Kristeleit R.

Br J Cancer. 2019 Feb;120(4):379-386. doi: 10.1038/s41416-019-0377-x. Epub 2019 Jan 25.

7.

Detection of circulating tumour cell clusters in human glioblastoma.

Krol I, Castro-Giner F, Maurer M, Gkountela S, Szczerba BM, Scherrer R, Coleman N, Carreira S, Bachmann F, Anderson S, Engelhardt M, Lane H, Evans TRJ, Plummer R, Kristeleit R, Lopez J, Aceto N.

Br J Cancer. 2018 Aug;119(4):487-491. doi: 10.1038/s41416-018-0186-7. Epub 2018 Aug 1.

8.

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.

Shapiro GI, Kristeleit RS, Burris HA, LoRusso P, Patel MR, Drew Y, Giordano H, Maloney L, Watkins S, Goble S, Jaw-Tsai S, Xiao JJ.

Clin Pharmacol Drug Dev. 2019 Jan;8(1):107-118. doi: 10.1002/cpdd.575. Epub 2018 May 25.

9.

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R.

Eur J Cancer. 2018 Jun;96:6-16. doi: 10.1016/j.ejca.2018.03.012. Epub 2018 Apr 13.

PMID:
29660598
10.

Mainstreamed genetic testing for women with ovarian cancer: first-year experience.

Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T, Side L.

J Med Genet. 2019 Mar;56(3):195-198. doi: 10.1136/jmedgenet-2017-105140. Epub 2018 Mar 13.

PMID:
29535157
11.

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS.

Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4.

12.

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy.

Milani A, Kristeleit R, McCormack M, Raja F, Luvero D, Widschwendter M, MacDonald N, Mould T, Olatain A, Hackshaw A, Ledermann JA.

ESMO Open. 2017 Jan 31;1(6):e000117. doi: 10.1136/esmoopen-2016-000117. eCollection 2016.

13.

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.

Kristeleit R, Davidenko I, Shirinkin V, El-Khouly F, Bondarenko I, Goodheart MJ, Gorbunova V, Penning CA, Shi JG, Liu X, Newton RC, Zhao Y, Maleski J, Leopold L, Schilder RJ.

Gynecol Oncol. 2017 Sep;146(3):484-490. doi: 10.1016/j.ygyno.2017.07.005. Epub 2017 Jul 8.

PMID:
28698009
14.

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA.

Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6.

PMID:
28273485
15.

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.

Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R.

Clin Cancer Res. 2017 Aug 1;23(15):4095-4106. doi: 10.1158/1078-0432.CCR-16-2796. Epub 2017 Mar 6.

16.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA.

Eur J Cancer. 2017 Jan;70:111-121. doi: 10.1016/j.ejca.2016.09.004. Epub 2016 Dec 1.

PMID:
27914241
17.

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.

Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.

18.

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.

Spicer J, Irshad S, Ang JE, Enting D, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J.

Cancer Chemother Pharmacol. 2017 Jan;79(1):17-27. doi: 10.1007/s00280-016-3189-1. Epub 2016 Nov 21.

19.

Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.

Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, MacDonald N, Ledermann JA.

Gynecol Oncol. 2017 Jan;144(1):57-60. doi: 10.1016/j.ygyno.2016.11.001. Epub 2016 Nov 5.

PMID:
27825669
20.

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.

Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M, Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R.

Clin Ther. 2016 Oct;38(10):2286-2299. doi: 10.1016/j.clinthera.2016.08.010. Epub 2016 Oct 10.

PMID:
27745744
21.

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.

Konecny GE, Kristeleit RS.

Br J Cancer. 2016 Nov 8;115(10):1157-1173. doi: 10.1038/bjc.2016.311. Epub 2016 Oct 13. Review.

22.

Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer.

Lemech CR, Ensell L, Paterson JC, Eminowicz G, Lowe H, Arora R, Arkenau HT, Widschwendter M, MacDonald N, Olaitan A, Mould T, Meyer T, Hartley J, Mitra A, Ledermann JA, McCormack M, Kristeleit RS.

Oncology. 2016;91(1):48-54. doi: 10.1159/000445999. Epub 2016 Jun 3.

PMID:
27256106
23.

Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.

Kristeleit RS, Miller RE, Kohn EC.

Am Soc Clin Oncol Educ Book. 2016;35:e259-68. doi: 10.14694/EDBK_159086. Review.

24.

Homologous recombination deficiency and ovarian cancer.

Ledermann JA, Drew Y, Kristeleit RS.

Eur J Cancer. 2016 Jun;60:49-58. doi: 10.1016/j.ejca.2016.03.005. Epub 2016 Apr 9. Review.

PMID:
27065456
25.

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.

Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema MP, Plummer R, Kristeleit R, Evans TR, Schellens JH.

Invest New Drugs. 2016 Jun;34(3):329-37. doi: 10.1007/s10637-016-0344-9. Epub 2016 Apr 2.

PMID:
27039386
26.

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, Solca F, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J, Spicer J.

Eur J Cancer. 2015 Nov;51(16):2275-84. doi: 10.1016/j.ejca.2015.07.041. Epub 2015 Aug 18.

PMID:
26296295
27.

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.

Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R.

Lancet Oncol. 2015 Jun;16(6):686-94. doi: 10.1016/S1470-2045(15)70159-2. Epub 2015 May 13.

28.

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, Mazina K, Lin R, Wu J, Fredrickson J, Spoerke JM, Lackner MR, Yan Y, Friedman LS, Kaye SB, Derynck MK, Workman P, de Bono JS.

Clin Cancer Res. 2015 Jan 1;21(1):77-86. doi: 10.1158/1078-0432.CCR-14-0947. Epub 2014 Nov 4.

29.

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.

McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M, Hall G, Clamp A, Earl H, Banerjee S, Kristeleit R, Raja F, Feeney A, Lawrence C, Dawson-Athey L, Persic M, Khan I.

Ann Oncol. 2014 Oct;25(10):1988-95. doi: 10.1093/annonc/mdu363. Epub 2014 Jul 28.

30.

An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials.

Pinato DJ, Stavraka C, Flynn MJ, Forster MD, O'Cathail SM, Seckl MJ, Kristeleit RS, Olmos D, Turnbull SJ, Blagden SP.

PLoS One. 2014 Jan 7;9(1):e83279. doi: 10.1371/journal.pone.0083279. eCollection 2014.

31.

Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.

Stavraka C, Pinato DJ, Turnbull SJ, Flynn MJ, Forster MD, O'Cathail SM, Babar S, Seckl MJ, Kristeleit RS, Blagden SP.

Cancer. 2014 Jan 15;120(2):262-70. doi: 10.1002/cncr.28381. Epub 2013 Oct 8.

32.

First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.

Brunetto AT, Ang JE, Lal R, Olmos D, Molife LR, Kristeleit R, Parker A, Casamayor I, Olaleye M, Mais A, Hauns B, Strobel V, Hentsch B, de Bono JS.

Clin Cancer Res. 2013 Oct 1;19(19):5494-504. doi: 10.1158/1078-0432.CCR-13-0735. Epub 2013 Sep 24.

33.

A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.

Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, Fourneau N, Hellemans P, Elsayed Y, McClue S, Smit JW, Forslund A, Phelps C, Camm J, Evans TR, de Bono JS, Banerji U.

Clin Cancer Res. 2013 Aug 1;19(15):4262-72. doi: 10.1158/1078-0432.CCR-13-0312. Epub 2013 Jun 5.

34.

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.

Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, Schellens JH, Kramar A, Kristeleit RS, Arkenau HT, Kaye SB, Penel N.

Br J Cancer. 2012 Sep 25;107(7):1025-30. doi: 10.1038/bjc.2012.371. Epub 2012 Aug 21.

35.

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.

Banerji U, van Doorn L, Papadatos-Pastos D, Kristeleit R, Debnam P, Tall M, Stewart A, Raynaud F, Garrett MD, Toal M, Hooftman L, De Bono JS, Verweij J, Eskens FA.

Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165.

36.

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.

Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB, Molife LR.

Nat Rev Clin Oncol. 2011 May;8(5):302-6. doi: 10.1038/nrclinonc.2011.42. Epub 2011 Apr 5.

PMID:
21468130
37.

Optimal treatment for relapsing ovarian cancer.

Ledermann JA, Kristeleit RS.

Ann Oncol. 2010 Oct;21 Suppl 7:vii218-22. doi: 10.1093/annonc/mdq377. Review.

38.

Early oncology clinical trial design in the era of molecular-targeted agents.

Brunetto AT, Kristeleit RS, de Bono JS.

Future Oncol. 2010 Aug;6(8):1339-52. doi: 10.2217/fon.10.92. Review.

PMID:
20799878
39.

Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers.

Jones A, Lechner M, Fourkala EO, Kristeleit R, Widschwendter M.

Epigenomics. 2010 Feb;2(1):9-38. doi: 10.2217/epi.09.47. Review.

PMID:
22122746
40.

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.

de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, Workman P, Kaye S, Rowinsky EK, Aherne W, Atadja P, Scott JW, Patnaik A.

Clin Cancer Res. 2008 Oct 15;14(20):6663-73. doi: 10.1158/1078-0432.CCR-08-0376.

41.

Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.

Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, Workman P, Leach MO, Beloueche-Babari M.

Neoplasia. 2008 Apr;10(4):303-13.

42.

Histone deacetylase inhibitors: emerging anticancer therapeutic agents?

Kristeleit R, Fong P, Aherne GW, de Bono J.

Clin Lung Cancer. 2005 Sep;7 Suppl 1:S19-30. Review.

PMID:
16159416
43.

Histone modification enzymes: novel targets for cancer drugs.

Kristeleit R, Stimson L, Workman P, Aherne W.

Expert Opin Emerg Drugs. 2004 May;9(1):135-54. Review.

PMID:
15155140

Supplemental Content

Loading ...
Support Center